Provisions in the prescription monitoring program changed.

HF 2624 amends Minnesota's prescription monitoring program (PMP) to update reporting requirements for controlled substances. The bill specifically adds butalbital, gabapentin, and FDA-approved opioid overdose reversal agents to the list of "controlled reportable substances" tracked in the PMP. It requires pharmacies and dispensers to report detailed patient and prescription data (including name, address, date of birth, drug name/strength, and quantity dispensed) electronically, while clarifying exemptions for inpatient hospital care, drug samples, and prescriptions mailed to other states. This bill directly affects pharmacists, hospitals, and prescribers who dispense controlled substances within Minnesota.